Williams Marc J, Werner Benjamin, Barnes Chris P, Graham Trevor A, Sottoriva Andrea
Evolution and Cancer Laboratory, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.
Department of Cell and Developmental Biology, University College London, London WC1E 6BT, UK.
Nat Genet. 2016 Mar;48(3):238-244. doi: 10.1038/ng.3489. Epub 2016 Jan 18.
Despite extraordinary efforts to profile cancer genomes, interpreting the vast amount of genomic data in the light of cancer evolution remains challenging. Here we demonstrate that neutral tumor evolution results in a power-law distribution of the mutant allele frequencies reported by next-generation sequencing of tumor bulk samples. We find that the neutral power law fits with high precision 323 of 904 cancers from 14 types and from different cohorts. In malignancies identified as evolving neutrally, all clonal selection seemingly occurred before the onset of cancer growth and not in later-arising subclones, resulting in numerous passenger mutations that are responsible for intratumoral heterogeneity. Reanalyzing cancer sequencing data within the neutral framework allowed the measurement, in each patient, of both the in vivo mutation rate and the order and timing of mutations. This result provides a new way to interpret existing cancer genomic data and to discriminate between functional and non-functional intratumoral heterogeneity.
尽管在分析癌症基因组方面付出了巨大努力,但根据癌症进化来解释大量的基因组数据仍然具有挑战性。在这里,我们证明中性肿瘤进化导致肿瘤组织样本的下一代测序报告的突变等位基因频率呈幂律分布。我们发现,中性幂律高精度地拟合了来自14种类型和不同队列的904种癌症中的323种。在被确定为中性进化的恶性肿瘤中,所有的克隆选择似乎都发生在癌症生长开始之前,而不是在后来出现的亚克隆中,从而导致了许多负责肿瘤内异质性的乘客突变。在中性框架内重新分析癌症测序数据,可以测量每个患者体内的突变率以及突变的顺序和时间。这一结果为解释现有的癌症基因组数据以及区分功能性和非功能性肿瘤内异质性提供了一种新方法。